Diabetic nephropathy

Principles of Diabetes Mellitus

Volumn , Issue , 2010, Pages 347-355

  Winchester, James F ^a   Feinfeld, Donald A ^a   Harbord, Nikolas B ^a   Dubrow, Alan ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649269549     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-09841-8_22     Document Type: Chapter

References (77)

1. United States Renal Data System: 2006 Annual Data Report. Bethesda: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 2006.
2. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - a growing challenge. N Eng J Med. 2007;356:213-215.
3. Ramezani M, Ghoddousi K, Hashemi M, et al. Diabetes as the cause of end-stage renal disease affects the pattern of post kidney transplant rehospitalizations. Transplant Proc. 2007;39:966-969.
4. Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation. 2007;83:1027-1034.
5. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007;56:161-165.
6. Osterby R, Parving HH, Hommel E, et al. Glomerular structure and function in diabetic nephropathy. Early to advanced stages. Diabetes. 1990;39:1057-1063.
7. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999;56:1627-1637.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
9. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med. 2007 Sep;120(9 Suppl 2): S12-S17.
10. Cavusoglu AC, Bilgili S, Alaluf A, et al. Vascular endothelial growth factor level in the serum of diabetic patients with retinopathy. Ann Ophthalmol (Skokie). 2007;39:205-208.
11. Ryan GJ. New pharmacologic approaches to treating diabetic retinopathy. Am J Health Syst Pharm. 2007;64(17 Suppl 12): S15-S21.
12. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930.
13. Gruden G, Zonca S, Hayward A, et al. Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent. Diabetes. 2000;49:655-661.
14. Lassila M, Jandeleit-Dahm K, Seah KK, et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol. 2004;15:2125-2138.
15. Izquierdo A, Lopez-Luna P, Ortega A, et al. The parathyroid hormone-related protein system and diabetic nephropathy outcome in streptozotocin-induced diabetes. Kidney Int. 2006;69:2171-2177.
16. Wang Y, Zhou J, Minto AW, et al. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection fro diabetic nephropathy. Kidney Int. 2006;70:882-891.
17. Zhang Z, Yuan W, Sun L, et al. 1, 25 dihydroxy vitamin D3 targeting of NFκB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 2007;72:193-201.
18. Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2008;73: 163-167.
19. Earle KS, Walker J, Hill C, et al. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med. 1992;325:673-677.
20. Krolewski A, Fogarty D, Warram J. Hypertension and nephropathy in diabetes mellitus: what is inherited and what is acquired? Diabetes Res Clin Pract. 1998;39 Suppl:S1-S14.
21. Strojek K, Grzeszczak W, Ritz E. Risk factors for development of diabetic nephropathy: a review. Nephrol Dial Transplant. 1997;12(Suppl 2):24-26.
22. Fioretto P, Steffes M, Barbosa J, et al. Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes. 1999;48:865-869.
23. Canani L, Gerchman F, Gross J. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes. 1999;48:909-913.
24. Marshall SM. Recent advances in diabetic nephropathy. Postgrad Med J. 2004;80:624-633.
25. Krolewski A, Canessa M, Warram J, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med. 1998;318:140-145.
26. Fujita J, Tsuda K, Seno M, et al. Erythrocyte sodium-lithium countertransport activity as a marker of predisposition to hypertension and diabetic nephropathy in NIDDM. Diabetes Care. 1994;17:977-982.
27. Lindsay R, Little J, Jaap A, et al. Diabetic nephropathy in associated with an increased familial risk of stroke. Diabetes Care. 1999;22:422-425.
28. Freire MB, van Dijk DJ, Erman A, et al. DNA polymorphisms in the ACE gene, serum ACE activity and the risk of nephropathy in insulin-dependent diabetes mellitus. Nephrol Dial Transplant. 1998;13:2553-2558.
29. Vleming LJ, van der Pijl JW, Lemkes HH, et al. The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol. 1999;51:133-140.
30. Miller JA, Scholey JW. The impact of renin-angiotensin system polymorphisms on physiological and pathophysiological processes in humans. Curr Opin Nephrol Hypertens. 2004;13:101-106.
31. Mogensen CE. Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus. Scand J Clin Lab Invest. 1971;28:91-100.
32. Nowack R, Raum E, Blum W, et al. Renal hemodynamics in recent-onset type II diabetes. Am J Kidney Dis. 1992;20:342-347.
33. Parving HH, Chaturvedi N, Viberti GC, et al. Does microalbuminuria predict diabetic nephropathy? Diabetes Care. 2002;25:406-407.
34. Stephenson JM, Kenny S, Stevens LK, et al. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes. Diabet Med. 1995;12:149-155.
35. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension. 1995;26:869-879.
36. Herlitz H, Aurell M, Holm G, et al. Renal degradation of insulin in patients with renal hypertension. Scand J Urol Nephrol. 1983;17:109-113.
37. Feneberg R, Sparber M, Veldhuis JD, et al. Altered temporal organization of plasma insulin oscillations in chronic renal failure. J Clin Endocrinol Metab. 2002;87:1965-1973.
38. Chimori K, Miyazaki S, Kosaka J, et al. The significance of autonomic neuropathy in the elevation of inactive renin in diabetes mellitus. Clin Exp Hypertens. 1987;9:1-18.
39. Oh MS, Carroll HJ, Clemmons JE, et al. A mechanism for hyporeninemic hypoaldosteronism in chronic renal disease. Metabolism. 1974;23:1157-1166.
40. Vander AJ. Direct effects of potassium on renin secretion and renal function. Am J Physiol. 1970;219:455-459.
41. Sebastian A, Schambelan M, Lindenfeld S, et al. Amelioration of metabolic acidosis with fludrocortisone therapy in hyporeninemic hypoaldosteronism. N Engl J Med. 1977;297:576-583.
42. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007;335:497.
43. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc. 2007;298:1180-1188.
44. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. J Am Med Assoc. 2007;298:1189-1195.
45. DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetic Control and Complications Trial. Kidney Int. 1995;47:1703-1720.
46. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Eng J Med. 1993;329:304-309.
47. Tuttle KR, Bruton JL. Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int. 1992;42:167-173.
48. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. J Am Med Assoc. 2003;290: 2159-2167.
49. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
50. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macro vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000;321:405-412.
51. McCormack J, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ. 2000;320:1720-1723.
52. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
53. Poulsen PL, Ebbehøj E, Hansen KW, et al. Characteristics and prognosis of normoalbuminuric type 1 diabetic patients. Diabetes Care. 1999;22(S2):B72-B75.
54. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792.
55. Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982-988.
56. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J. 2000;321:412-419.
57. The JNC 7 Report. J Am Med Assoc. 2003;289:2560-2572.
58. Hypertension management in adults with diabetes. Diabetes Care. 2004;27(S1):S65-S67.
59. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. NEngl J Med. 1993;329:1456-1462.
60. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
61. Parving HH, Brenner BM, Cooper ME, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. NEng J Med. 2001;345:870-878.
62. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
63. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. NEngl J Med. 2001;345:851-860.
64. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J. 1998;317:713-720.
65. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-1097.
66. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026-2033.
67. Green EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model. JCI. 1996;98:1063-1068.
68. Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64-68.
69. Schjoedt KJ, Anderen S, Rossing P, et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47:1936-1939.
70. van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10:803-812.
71. Hollenberg NK, Osei SY, Lansang MC, et al. Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. J Renin Angiotensin Aldosterone Syst. 2001;2:14-18.
72. Weinberg AJ, Zappe DH, Ashton M, et al. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol. 2004;24:340-345.
73. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J. 2000;321:1440-1444.
74. van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285-2292.
75. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940-951.
76. Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17: 2006-2016.
77. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.